

control protocols in biomedical-device development and production.

- 1 Cardis, D T, Reinhold, R B, Woodruff, P. W. W. and Fine, J, *Lancet*, 1972, 1381.
- 2 Levin, J. *et al.*, *Ann. Int. Med.*, 1972, 76, 1.
- 3 Reinhold, R. B and Fine, J, *Proc. Soc. Exp Biol Med*, 1971, 134, 334.
- 4 Kreeftenberg, J G., Loggen, H. G., Van Ramhorst, J. D and Benvery, E. C., *Develop. Biol. Std.*, 1977, 34, 15
- 5 Cooper, J F., Hochstein, H D and Seligmann, J. B., *Bull. Parenter Drug Assoc.*, 1972, 26, 153.
- 6 Wiblin, C. N., in *Animal Cell Biotechnology* (eds. Speir, R. E. and Griffiths, J. B).

- 7 United States Pharmacopoeia, LXX, Rockville, MD, USA. United States Pharmacopoeia Convention Inc 1985, 1181.
- 8 Sigma Tech. Bull., No. 210, 1970.

We thank Mrs Lizzy Michael for technical assistance.

K. RATHINAM  
H. VIJAYAKUMAR

*Biomedical Technology Wing  
Sree Chitra Tirunal Institute  
for Medical Sciences and Technology  
Trivandrum 695 012*

two  $\beta$ -galactoside-binding lectins in human and murine tumour cells. Interestingly, both the  $\beta$ -galactoside-containing glycopeptides from asialofetum and monoclonal antibodies to the lectins could inhibit tumour-cell aggregation as well as attachment to the substratum. Further evidence for an active role of glycoconjugate-lectin interaction in growth regulation was provided by the recent results of Sanford and Harris-Hooker<sup>9</sup>, who found that rat-lung galaptin was mitogenic towards pulmonary arterial cells and smooth-muscle cells in culture (as measured by incorporation of radio-labelled thymidine) in a sugar-dependent manner.

Changes in oligosaccharide structures *vis-à-vis* their corresponding lectins is a popular topic in cancer research today. Inasmuch as a tumour is regarded as a retrogression to the embryonic stage, it will be interesting to examine if reexpression of differentiation antigens, like the stage-specific embryonic antigen [Gal  $\beta$ 1 $\rightarrow$ 4 (Fuc $\alpha$ 1 $\rightarrow$ 3) GlcNAc-R] or oversialylated form of neural cell adhesion molecule, and their recognition by lectins facilitate tumour mobility and anchorage.

1. Kahn, H. J., Brodt, P. and Baumal, R., *Am. J. Pathol.*, 1988, 132, 180.
2. Penno, M. B. *et al.*, *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6057.
3. Dennis, J. W., *Cancer Surveys*, 1988, 7, 573.
4. Stutman, Q., Dien, P., Wisuun, R. F. and Lattime, E. C., *Proc. Natl. Acad. Sci. USA*, 1980, 77, 2895
5. Ahrens, P. B. and Ankel, H., *J. Biol. Chem.*, 1987, 262, 7575.
6. Dennis, J. W., Waller, C., Timple, R. and Schirmacher, V., *Nature*, 1982, 300, 274.
7. Leffler, H., Masiarz, F. R. and Barondes, S. H., *Biochemistry*, 1989, 28, 9222.
8. Lotan, R. and Raz, A., *J. Cell. Biochem.*, 1988, 37, 107.
9. Sanford, G. L. and Harris-Hooker, S., *FASEB J.*, 1990, 4, 2912.

P. S. APPUKUTTAN  
*Neurochemistry Division  
Sree Chitra Tirunal Institute for  
Medical Sciences and Technology  
Trivandrum 695 011*

## Surface sugars of cancer cells: The sweeter the deadlier?

In tumorigenesis and metastasis of tumours, although factors such as protease production and organ-specific micro-environment have been implicated in target selection, recent evidences assign a decisive role to oligosaccharide structures on cell-surface glycoconjugates, interaction of which with sugar-specific molecules on other cells or on extracellular matrix governs cell sociology. For example, in reactivity towards the carbohydrate-binding proteins (lectins) from peanut (peanut agglutinin, PNA), soybean (soybean agglutinin, SBA) and *Ulex europaeus* (*Ulex europaeus* agglutinin-1, UEA-1), primary subcutaneous tumours induced in rats using Lewis lung carcinoma cells had the phenotype PNA<sup>-</sup>, SBA<sup>-</sup>, UEA-1<sup>-</sup>, while its liver and lung metastases were PNA<sup>+</sup>, SBA<sup>+</sup>, UEA-1<sup>-</sup>, and PNA<sup>+</sup>, SBA<sup>+</sup>, UEA-1<sup>+</sup> respectively<sup>1</sup>. Penno *et al.*<sup>2</sup> observed in *in vitro* studies that galactosylation in general, and that of a 110-kDa cell-surface glycoprotein in particular, correlates with invasiveness of a murine adrenal carcinoma cell line. In more detailed investigations by Dennis and colleagues<sup>3</sup>, using the highly metastatic lymphoreticular tumour cell line MDAY-D2 and its non-metastatic glycosylation mutants, two events have been shown to enhance metastatic potential: (i) sialylation of oligosaccharides and (ii) addition of  $\beta$ 1 $\rightarrow$ 6

branched *N*-acetylglucosamine (GlcNAc) to which galactose is also attached as part of a tri- or tetra-antennary structure in N-linked oligosaccharides. The above conclusion is supported by earlier *in vitro* tests that showed that natural-killer (NK)-cell attachment to cells is inversely proportional to their sialylation and to masking of mannose groups by substitution such as by  $\beta$ 1 $\rightarrow$ 6 GlcNAc branching<sup>4</sup>. Also, swainsonine, an alkaloid that inhibits oligosaccharide processing, has been found to reduce growth and increase susceptibility to NK cells of tumour cells *in vitro*<sup>5</sup>. MDAY-D2, unlike its undersialylated mutants or its desialylated derivative, adhered very weakly to plastic surfaces coated with fibronectin, laminin or collagen type IV, thus providing an explanation for its mobility and metastasis<sup>6</sup>.

Recent results suggest that endogenous lectins, as complementary molecules or receptors to oligosaccharide groups, may be most effective, though glycosidases and anticarbohydrate antibodies may be operative. Many animal tissues contain a  $\beta$ -galactoside-binding lectin (galaptin)<sup>7</sup>. Galaptins are easily solubilized from tissue by soluble galactosides, indicating their association *in vivo* with complementary glycoconjugates.

Lotan and Raz<sup>8</sup> also demonstrated